Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals is a pioneering biotechnology company specializing in the discovery and development of RNA-targeted therapeutics. As the inventor of antisense oligonucleotide (ASO) technology, Ionis has established itself as a leader in RNA therapeutics, focusing on treating serious genetic, rare, neurological, and cardiovascular diseases. The company has transitioned from a research-focused biotech to a fully integrated, commercial-stage pharmaceutical company with multiple approved medicines and a robust, industry-leading pipeline of investigational therapeutics. Ionis employs advanced technology platforms, including antisense inhibitors, RNAi therapeutics, and CRISPR-based approaches, to precisely target and interact with RNA and DNA. The company frequently utilizes a collaborative business model, partnering with major pharmaceutical companies to advance its pipeline while maintaining a core focus on innovation and long-term value creation for patients and stakeholders.